

Supporting information

# Jejucarbazoles A-C, Carbazole Glycosides with Indoleamine 2,3-dioxygenase 1 Inhibitory Activity from *Streptomyces* sp. KCB15JA151

*Gil Soo Kim*<sup>‡ ab</sup>, *Jun-Pil Jang*<sup>‡ a</sup>, *Mincheol Kwon*<sup>ab</sup>, *Tae Hoon Oh*<sup>ac</sup>, *Kyung Taek Heo*<sup>ab</sup>,  
*Byeongsan Lee*<sup>ac</sup>, *Jung-Sook Lee*<sup>d</sup>, *Sung-Kyun Ko*<sup>a</sup>, *Young-Soo Hong*<sup>ab</sup>, *Jong Seog Ahn*<sup>\*ab</sup>,  
and *Jae-Hyuk Jang*<sup>\*ab</sup>

<sup>a</sup> Anticancer Agent Research Center, Korea Research Institute of Bioscience and  
Biotechnology, Cheongju 28116, Korea

<sup>b</sup> Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of  
Science and Technology, Daejeon 34113, Korea

<sup>c</sup> College of Pharmacy, Chungbuk National University, Cheongju, 28160, Korea

<sup>d</sup> Korean Collection for Type Cultures, Korea Research Institute of Bioscience and  
Biotechnology, Jeongeup 56212, Korea

<sup>‡</sup>These authors contributed equally to this work.

## Table of Contents

- Fig. S1.** UPLC-UV spectrum of compound **1** in MeCN-H<sub>2</sub>O containing 0.05% Formic acid
- Fig. S2.** IR spectrum of compound **1**
- Fig. S3.** CD spectrum of compound **1**
- Fig. S4.** HR-ESI-TOF-MS negative spectrum in compound **1**
- Fig. S5.** MS/MS fragmentation spectrum of compound **1** (parent ion, 514.39 [M + H - H<sub>2</sub>O]<sup>+</sup>)
- Fig. S6.** MS/MS fragmentation spectrum of compound **1** (parent ion, 530.60 [M - H]<sup>-</sup>)
- Fig. S7.** <sup>1</sup>H NMR spectrum of compound **1** in Acetone-*d*<sub>6</sub>
- Fig. S8.** <sup>13</sup>C NMR spectrum of compound **1** in Acetone-*d*<sub>6</sub>
- Fig. S9.** COSY NMR spectrum of compound **1** in Acetone-*d*<sub>6</sub>
- Fig. S10.** HSQC-DEPT NMR spectrum of compound **1** in Acetone-*d*<sub>6</sub>
- Fig. S11.** HMBC NMR spectrum of compound **1** in Acetone-*d*<sub>6</sub>
- Fig. S12.** ROESY NMR spectrum of compound **1** in Acetone-*d*<sub>6</sub>
- Fig. S13.** The relative configuration of the sugar unit in compound **1**
- Fig. S14.** LC-MS analysis for thiocarbamate derivatives of the sugar unit in **1**
- Fig. S15.** UPLC-UV spectrum of compound **2** in MeCN-H<sub>2</sub>O containing 0.05% Formic acid
- Fig. S16.** IR spectrum of compound **2**
- Fig. S17.** CD spectrum of compound **2**
- Fig. S18.** HR-ESI-TOF-MS negative spectrum in compound **2**
- Fig. S19.** MS/MS fragmentation spectrum of compound **2** (parent ion, 532.34 [M + H]<sup>+</sup>)
- Fig. S20.** <sup>1</sup>H NMR spectrum of compound **2** in CD<sub>3</sub>OD
- Fig. S21.** <sup>13</sup>C NMR spectrum of compound **2** in CD<sub>3</sub>OD
- Fig. S22.** COSY NMR spectrum of compound **2** in CD<sub>3</sub>OD
- Fig. S23.** HSQC-DEPT NMR spectrum of compound **2** in CD<sub>3</sub>OD
- Fig. S24.** HMBC NMR spectrum of compound **2** in CD<sub>3</sub>OD
- Fig. S25.** ROESY NMR spectrum of compound **2** in CD<sub>3</sub>OD
- Fig. S26.** UPLC-UV spectrum of compound **3** in MeCN-H<sub>2</sub>O containing 0.05% Formic acid
- Fig. S27.** IR spectrum of compound **3**
- Fig. S28.** HR-ESI-TOF-MS positive spectrum in compound **3**
- Fig. S29.** HR-ESI-TOF-MS negative spectrum in compound **3**
- Fig. S30.** MS/MS fragmentation spectrum of compound **3** (parent ion, 512.56 [M - H]<sup>-</sup>)
- Fig. S31.** <sup>1</sup>H NMR spectrum of compound **3** in CD<sub>3</sub>OD

**Fig. S32.**  $^{13}\text{C}$  NMR spectrum of compound **3** in  $\text{CD}_3\text{OD}$

**Fig. S33.** COSY NMR spectrum of compound **3** in  $\text{CD}_3\text{OD}$

**Fig. S34.** HSQC-DEPT NMR spectrum of compound **3** in  $\text{CD}_3\text{OD}$

**Fig. S35.** HMBC NMR spectrum of compound **3** in  $\text{CD}_3\text{OD}$

**Fig. S36.** ROESY NMR spectrum of compound **3** in  $\text{CD}_3\text{OD}$

**Fig. S37.** Chemical structures of neocarazostains and carquinostatins

**Fig. S38.** Comparison of the putative jejucarbazole biosynthetic gene cluster in *Streptomyces* sp. KCB15JA151 with neocarazostatin and carquinostatin gene clusters


**Fig. S39.** IDO1 inhibition rate of jejucarbazoles A-C

**Table S1.** Predicted functions and homologues in the putative jejucarbazole biosynthetic gene cluster


**Table S2.** Docking scores of compound **1-3** against the holo-IDO1 and apo-IDO1

**Fig. S40.** Molecular-docking analysis of compound **1** with the apo-IDO1 enzyme


**Fig. S41.** Molecular-docking analysis of compound **2** with the apo-IDO1 enzyme




**Fig. S1.** UPLC-UV spectrum of compound **1** in MeCN-H<sub>2</sub>O containing 0.05% Formic acid



**Fig. S2.** IR spectrum of compound **1**




**Fig. S3.** CD spectrum of compound **1**




**Fig. S4.** HR-ESI-TOF-MS negative spectrum in compound **1**

KKS\_6E#1356-1439 RT: 10.98-11.69 AV: 4 NL: 1.77E5  
T: ITMS + c ESI d Full ms2 514.39@cid35.00 [130.00-1040.00]




**Fig. S5.** MS/MS fragmentation spectrum of compound 1 (parent ion, 514.39 [M + H - H<sub>2</sub>O]<sup>+</sup>)


KKS\_6E#1365 RT: 11.06 AV: 1 NL: 7.00E4  
F: ITMS - c ESI d Full ms2 530.60@cid35.00 [135.00-1075.00]




**Fig. S6.** MS/MS fragmentation spectrum of compound 1 (parent ion, 530.60 [M - H]<sup>-</sup>)



Jejucarbazole A (1)




**Fig. S7.** <sup>1</sup>H NMR spectrum of compound **1** in Acetone-*d*<sub>6</sub>




**Fig. S8.**  $^{13}\text{C}$  NMR spectrum of compound **1** in Acetone- $d_6$







**Fig. S9.** COSY NMR spectrum of compound **1** in Acetone- $d_6$




**Fig. S10.** HSQC-DEPT NMR spectrum of compound **1** in Acetone- $d_6$





**Fig. S11.** HMBC NMR spectrum of compound **1** in Acetone- $d_6$




**Fig. S12.** ROESY NMR spectrum of compound **1** in Acetone- $d_6$




 ROESY       Coupling constant


**Fig. S13.** The relative configuration of the sugar unit in compound **1**



**Fig. S14.** LC-MS analysis for thiocarbamate derivatives of the sugar unit in **1** (Selected ion at  $m/z$  461.0-461.99  $[M+H]^+$ )



**Fig. S15.** UPLC-UV spectrum of compound **2** in MeCN-H<sub>2</sub>O containing 0.05% Formic acid



**Fig. S16.** IR spectrum of compound **2**




Fig. S17. CD spectrum of compound 2






Fig. S18. HR-ESI-TOF-MS negative spectrum in compound 2



KKS\_2E #375-683 RT: 5.88-10.30 AV: 6 NL: 3.22E5  
T: Total composite spectrum for 532.34



**Fig. S19.** MS/MS fragmentation spectrum of compound 2 (parent ion, 532.34 [M + H]<sup>+</sup>)



Jejucarbazole B (2)





Fig. S20. <sup>1</sup>H NMR spectrum of compound 2 in CD<sub>3</sub>OD





**Fig. S22.** COSY NMR spectrum of compound 2 in CD<sub>3</sub>OD




Fig. S23. HSQC-DEPT NMR spectrum of compound 2 in CD<sub>3</sub>OD




Fig. S24. HMBC NMR spectrum of compound 2 in CD<sub>3</sub>OD






Fig. S25. ROESY NMR spectrum of compound 2 in CD<sub>3</sub>OD



**Fig. S26.** UPLC-UV spectrum of compound **3** in MeCN-H<sub>2</sub>O containing 0.05% Formic acid



**Fig. S27.** IR spectrum of compound **3**






Fig. S28. HR-ESI-TOF-MS positive spectrum in compound 3






Fig. S29. HR-ESI-TOF-MS negative spectrum in compound 3



**Fig. S30.** MS/MS fragmentation spectrum of compound **3** (parent ion, 512.56 [M - H]<sup>-</sup>)



Jejucarbazole C (3)





Fig. S31. <sup>1</sup>H NMR spectrum of compound 3 in CD<sub>3</sub>OD



Jejudarbazole C (3)




Fig. S32. <sup>13</sup>C NMR spectrum of compound 3 in CD<sub>3</sub>OD




Fig. S33. COSY NMR spectrum of compound 3 in CD<sub>3</sub>OD




Fig. S34. HSQC-DEPT NMR spectrum of compound 3 in CD<sub>3</sub>OD




Fig. S35. HMBC NMR spectrum of compound 3 in CD<sub>3</sub>OD






Fig. S36. ROESY NMR spectrum of compound 3 in CD<sub>3</sub>OD





Neocarazostatin A: R = OH  
 Neocarazostatin B: R = H  
 Neocarazostatin C: R = OMe

Dihydroxyl type CA




Carquinostatin A: R = H  
 Carquinostatin B: R = OH


*ortho*-Quinone type CA

**Fig. S37.** Chemical structures of neocarazostains and carquinostatins


*Jejucarbazole putative Biosynthetic gene cluster*



*Neocarazostatin(NZS)*



*Carquinostatin (CQS)*




**Fig. S38.** Comparison of the putative jejucarbazole biosynthetic gene cluster in *Streptomyces* sp. KCB15JA151 with neocarazostatin (GenBank: LC406090.1) and carquinostatin (GenBank: KP657980.1) gene clusters.

**Table S1.** Predicted functions and homologues in the putative jejucarbazole biosynthetic gene cluster

Protein	Size (aa)	Predicted Function	Homologue in Neocarazostatin		Best match	
			Protein / GeneBank (residue)	Identity/Similarity	Organism / GeneBank (residue)	Identity/Similarity
15JA151_1_02780	133	Putative response regulatory protein			<i>Streptomyces sp.</i> WELS2 / WP_181792968.1 (133)	99 / 99
15JA151_1_02779	206	Heme-copper oxidase subunit III			<i>Streptomyces</i> / WP_030783240.1 (206)	100 / 100
15JA151_1_02778	270	C-type cytochrome			<i>Streptomyces eurythermus</i> / WP_189752509.1 (270)	100 / 100
15JA151_1_02777	352	Rieske 2Fe-2S domain-containing protein			<i>Streptomyces sp.</i> WELS2 / WP_181792970.1 (352)	99 / 100
15JA151_1_02776	545	Ubiquinol-cytochrome c reductase cytochrome b subunit			<i>Streptomyces achromogenes</i> / WP_030621189.1 (545)	97 / 96
15JA151_1_02775	417	Cytochrome P450	nzsA / ALL53314.1 (418)	65 / 79	<i>Streptomyces eurythermus</i> / WP_189752507.1 (417)	99 / 99
15JA151_1_02774	190	IPP isomerase	nzsC / ALL53316.1 (185)	75 / 81	<i>Streptomyces</i> / WP_030783251.1 (189)	99 / 98
15JA151_1_02773	325	aminotransferase	nzsD / ALL53317.1 (325)	64 / 74	<i>Streptomyces</i> / WP_051815689.1 (325)	97 / 98
15JA151_1_02772	79	ACP	nzsE / ALL53318.1 (80)	65 / 77	<i>Streptomyces</i> / WP_030783257.1 (79)	100 / 100

15JA151_1_02771	336	$\beta$ -ketosynthase III	nzsF / ALL53319.1 (337)	78 / 83	<i>Streptomyces achromogenes</i> / WP_189996525.1 (336)	98 / 98
15JA151_1_02770	337	Isoprenyl transferase	nzsG / ALL53320.1 (371)	64 / 81	<i>Streptomyces</i> / WP_030783263.1 (337)	98 / 98
15JA151_1_02769	592	Acetolactate synthase	nzsH / ALL53321.1 (593)	76 / 82	<i>Streptomyces achromogenes</i> / WP_189996527.1 (592)	97 / 98
15JA151_1_02768	226	Cyclase/aromatase	nzsI / ALL53322.1 (227)	80 / 89	<i>Streptomyces</i> / WP_030783270.1 (230)	99 / 100
15JA151_1_02767	331	$\beta$ -ketosynthase III	nzsJ / ALL53323.1 (331)	73 / 83	<i>Streptomyces</i> sp. WELS2 / WP_181792983.1 (349)	97 / 99
15JA151_1_02766	355	Rieske 2Fe-2S domain- containing protein			<i>Streptomyces</i> sp. DSM 40868 / WP_167512969.1 (355)	98 / 98
15JA151_1_02765	551	Cytochrome b N-terminal domain-containing protein			<i>Streptomyces eurythermus</i> / WP_189752499.1 (551)	97 / 99
15JA151_1_02764	354	Tryptophan biosynthesis	nzsB / ALL53315.1 (355)	76 / 87	<i>Streptomyces</i> / WP_030783280.1 (354)	99 / 99
15JA151_1_02763	453	Aminotransferase class V-fold PLP-dependent enzyme			<i>Streptomyces achromogenes</i> / WP_189996532.1 (453)	99 / 99


---




**Fig. S39.** IDO1 inhibition rate of jeju carbazoles A-C

**Table S2.** Docking scores of compounds **1-3** against holo-IDO1 enzyme (PDB id: 6AZU) with/without heme and apo-IDO1 enzyme (PDB id: 6AZV)

	Docking Score (Kcal/mol)		
	6AZU(holo-IDO1) with heme	6AZU(holo-IDO1) without heme	6AZV(apo-IDO1)
Compound <b>1</b>	-8.2	-8.4	-8.1
Compound <b>2</b>	-7.3	-7.7	-8.3
Compound <b>3</b>	-7.9	-8.3	-9.1



**Fig. S40.** Molecular-docking analysis of compound **1** with the apo-IDO1 enzyme (PDB id: 6AZV). (A) Putative binding mode for compound **1** with apo-IDO1. (B) Protein-ligand interaction profile between compound **1** with apo-IDO1. The gray dashed lines represent hydrophobic interactions; the blue dashed lines represent hydrogen bonds.



**Fig. S41.** Molecular-docking analysis of compound **2** with the apo-IDO1 enzyme (PDB id: 6AZV). (A) Putative binding mode for compound **2** with apo-IDO1. (B) Protein-ligand interaction profile between compound **2** with apo-IDO1. The gray dashed lines represent hydrophobic interactions; the blue dashed lines represent hydrogen bonds.